Showing results (1561-1570 of 14,091) with videos related to

Sort By:
Pageof 1,410
Gynecologic Oncology|November 30, 2016
Association between timing of cervical excision procedure to minimally invasive hysterectomy and surgical complicationsStephanie A Sullivan, Leslie H Clark, Allison S Staley, et al.
Gynecologic Oncology|December 3, 2016
Chemotherapy delay after primary debulking surgery for ovarian cancerBrandon-Luke L Seagle, Sharlay K Butler, Anna E Strohl, et al.
Gynecologic Oncology|March 5, 2015
PRSS3 expression is associated with tumor progression and poor prognosis in epithelial ovarian cancerRuiqiong Ma, Xue Ye, Hongyan Cheng, et al.
Gynecologic Oncology|March 5, 2015
Improving quality and decreasing cost in gynecologic oncology care. Society of gynecologic oncology recommendations for clinical practiceB J Rimel, William M Burke, Robert V Higgins, et al.
Gynecologic Oncology|March 11, 2015
Central nervous system metastasis in gynecologic cancer: symptom management, prognosis and palliative management strategiesAdam C Walter, Camille C Gunderson, Sara K Vesely, et al.
Gynecologic Oncology|August 25, 2020
Evaluation of outcomes in patients of cervical Cancer with lower one third vaginal involvement: A single institutional experienceLavanya Gurram, Roshankumar Patil, Supriya Chopra, et al.
Gynecologic Oncology|August 26, 2020
Sexual harassment and gender discrimination in gynecologic oncologyMarina Stasenko, Christopher Tarney, Kenneth Seier, et al.
Gynecologic Oncology|April 8, 2023
Ovarian preservation compared to oophorectomy in premenopausal women with early-stage, low-grade endometrial Cancer: A cost-effectiveness analysisMiriam L Hernandez-Zepeda, Elizabeth G Munro, Aaron B Caughey, et al.
Gynecologic Oncology|March 28, 2021
Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary-Clinical significance of BRCA2 gene variants in genomically stable tumorsXiaoming Zhang, Kyle Devins, Emily M Ko, et al.
Gynecologic Oncology|July 30, 2020
Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group studyKrishnansu S Tewari, Michael W Sill, Robert L Coleman, et al.
Pageof 1,410